Sharda Cropchem (SHARDACROP) Q3 25/26 earnings summary

Executive summary

• Achieved highest ever PAT for any year in nine months, with Q4 still ahead, driven by strong volume growth and improved product mix supported by accelerated product registrations.

• Expanded global presence with operations in 80+ countries and a robust distribution network.

• Maintained an asset-light business model, focusing on registrations, marketing, and distribution while outsourcing manufacturing.

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved, with auditors issuing an unmodified review opinion.

• Interim dividend of Rs. 6.00 per equity share declared for FY 2025-26, with record date set for February 6, 2026.

Financial highlights

• Q3 FY26 revenue grew 39% year-over-year to INR 1,289 crore; nine-month revenue up 29% to INR 3,203 crore.

• Q3 PAT at INR 145 crore, up 366% year-over-year; nine-month PAT at INR 362 crore, up 259% year-over-year.

• Q3 EBITDA at INR 246 crore, up 59% year-over-year, with EBITDA margin at 19.1%.

• Gross margin expanded by 220 bps to 34.9% in Q3; nine-month gross margin at 35%, up 500 bps year-over-year.

• Earnings per share reached Rs. 16.09 in Q3 FY26 and Rs. 40.15 in 9M FY26.

Outlook and guidance

• Q4 expected to be the strongest quarter, with full-year revenue guidance in the INR 5,400 crore range.

• FY 2027 volume growth of 15% and revenue growth of 15-20% anticipated.

• Gross margin of 35% and EBITDA margin of 18-20% expected to be sustainable into FY 2027.

• CapEx guidance for FY 2027 in the INR 450-500 crore range.

• Focus on expanding sales force, operational efficiencies, and further market penetration.